Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Relapsed/Refractory Waldenstrom's Macroglobulinemia
NCT00936611Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Jul 2009; status: completed.
02
Drugs
panobinostat
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00936611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936611.